206 related articles for article (PubMed ID: 17177381)
21. An O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-acetyl moiety.
Kim EJ; Perreira M; Thomas CJ; Hanover JA
J Am Chem Soc; 2006 Apr; 128(13):4234-5. PubMed ID: 16568991
[TBL] [Abstract][Full Text] [Related]
22. Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance.
Macauley MS; Bubb AK; Martinez-Fleites C; Davies GJ; Vocadlo DJ
J Biol Chem; 2008 Dec; 283(50):34687-95. PubMed ID: 18842583
[TBL] [Abstract][Full Text] [Related]
23. Defining the structural origin of the substrate sequence independence of O-GlcNAcase using a combination of molecular docking and dynamics simulation.
Martin JC; Fadda E; Ito K; Woods RJ
Glycobiology; 2014 Jan; 24(1):85-96. PubMed ID: 24134879
[TBL] [Abstract][Full Text] [Related]
24. O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes.
Park SY; Ryu J; Lee W
Exp Mol Med; 2005 Jun; 37(3):220-9. PubMed ID: 16000877
[TBL] [Abstract][Full Text] [Related]
25. MK-8719, a Novel and Selective
Wang X; Li W; Marcus J; Pearson M; Song L; Smith K; Terracina G; Lee J; Hong KK; Lu SX; Hyde L; Chen SC; Kinsley D; Melchor JP; Rubins DJ; Meng X; Hostetler E; Sur C; Zhang L; Schachter JB; Hess JF; Selnick HG; Vocadlo DJ; McEachern EJ; Uslaner JM; Duffy JL; Smith SM
J Pharmacol Exp Ther; 2020 Aug; 374(2):252-263. PubMed ID: 32493725
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of β-N-acetyl-D-glucosaminidase increases Akt1 activity in thyroid anaplastic cancer cells.
Krześlak A; Jóźwiak P; Lipińska A
Oncol Rep; 2011 Sep; 26(3):743-9. PubMed ID: 21637923
[TBL] [Abstract][Full Text] [Related]
27. Ac
Wang H; Guo J; Wang N; Wang J; Xue Q; Wang J; Liu W; Liu K; Cao X; Zhao W; Xi R; Niu Y; Wang P; Li J
Bioorg Med Chem Lett; 2019 Mar; 29(6):802-805. PubMed ID: 30713024
[TBL] [Abstract][Full Text] [Related]
28. Structural insights into the mechanism and inhibition of eukaryotic O-GlcNAc hydrolysis.
Rao FV; Dorfmueller HC; Villa F; Allwood M; Eggleston IM; van Aalten DM
EMBO J; 2006 Apr; 25(7):1569-78. PubMed ID: 16541109
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of NAM-thiazoline derivatives as novel O-GlcNAcase inhibitors.
Kong H; Chen W; Liu T; Lu H; Yang Q; Dong Y; Liang X; Jin S; Zhang J
Carbohydr Res; 2016 Jun; 429():54-61. PubMed ID: 27233493
[TBL] [Abstract][Full Text] [Related]
30. Design and synthesis of O-GlcNAcase inhibitors via 'click chemistry' and biological evaluations.
Li T; Guo L; Zhang Y; Wang J; Li Z; Lin L; Zhang Z; Li L; Lin J; Zhao W; Li J; Wang PG
Carbohydr Res; 2011 Jul; 346(9):1083-92. PubMed ID: 21514574
[TBL] [Abstract][Full Text] [Related]
31. The effects of O-GlcNAc alteration on Alzheimer-like neurodegeneration in SK-N-SH cells.
Ding N; Peng P; Chu YJ; Wang JJ; Chen SY; Arulthas R; Deng YQ
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):243-248. PubMed ID: 30181664
[TBL] [Abstract][Full Text] [Related]
32. Proteomics and PUGNAcity will overcome questioning of insulin resistance induction by nonselective inhibition of O-GlcNAcase.
Dehennaut V; Lefebvre T
Proteomics; 2013 Oct; 13(20):2944-6. PubMed ID: 23983178
[TBL] [Abstract][Full Text] [Related]
33. Elevation of Global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis.
Macauley MS; Shan X; Yuzwa SA; Gloster TM; Vocadlo DJ
Chem Biol; 2010 Sep; 17(9):949-58. PubMed ID: 20851344
[TBL] [Abstract][Full Text] [Related]
34. Computational analysis of human OGA structure in complex with PUGNAc and NAG-thiazoline derivatives.
de Alencar NA; Sousa PR; Silva JR; Lameira J; Alves CN; Martí S; Moliner V
J Chem Inf Model; 2012 Oct; 52(10):2775-83. PubMed ID: 22937904
[TBL] [Abstract][Full Text] [Related]
35. Streptozotocin-induced beta-cell death is independent of its inhibition of O-GlcNAcase in pancreatic Min6 cells.
Gao Y; Parker GJ; Hart GW
Arch Biochem Biophys; 2000 Nov; 383(2):296-302. PubMed ID: 11185566
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of O-GlcNAcase using a potent and cell-permeable inhibitor does not induce insulin resistance in 3T3-L1 adipocytes.
Macauley MS; He Y; Gloster TM; Stubbs KA; Davies GJ; Vocadlo DJ
Chem Biol; 2010 Sep; 17(9):937-48. PubMed ID: 20851343
[TBL] [Abstract][Full Text] [Related]
37. Caenorhabditis elegans ortholog of a diabetes susceptibility locus: oga-1 (O-GlcNAcase) knockout impacts O-GlcNAc cycling, metabolism, and dauer.
Forsythe ME; Love DC; Lazarus BD; Kim EJ; Prinz WA; Ashwell G; Krause MW; Hanover JA
Proc Natl Acad Sci U S A; 2006 Aug; 103(32):11952-7. PubMed ID: 16882729
[TBL] [Abstract][Full Text] [Related]
38. Structures of human O-GlcNAcase and its complexes reveal a new substrate recognition mode.
Li B; Li H; Lu L; Jiang J
Nat Struct Mol Biol; 2017 Apr; 24(4):362-369. PubMed ID: 28319083
[TBL] [Abstract][Full Text] [Related]
39. Proteome wide purification and identification of O-GlcNAc-modified proteins using click chemistry and mass spectrometry.
Hahne H; Sobotzki N; Nyberg T; Helm D; Borodkin VS; van Aalten DM; Agnew B; Kuster B
J Proteome Res; 2013 Feb; 12(2):927-36. PubMed ID: 23301498
[TBL] [Abstract][Full Text] [Related]
40. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase.
Wells L; Gao Y; Mahoney JA; Vosseller K; Chen C; Rosen A; Hart GW
J Biol Chem; 2002 Jan; 277(3):1755-61. PubMed ID: 11788610
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
